Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems is benefiting from stronger-than-expected commercial execution, with 2Q26 revenue of $29.1M beating the $26.3M consensus as HEPZATO KIT sales reached $27.1M and gross margin improved to about 90%. Management’s raised FY2026 revenue guidance to $104M-$108M reflects 1H26 volume growth, steady new patient starts near 0.5 per site per month, and operational fixes such as backup treatment teams that should reduce seasonal volatility. The company also has a healthier balance sheet with about $96M in cash and short-term equivalents, while expanding to 31 active treatment centers and targeting 37 by year-end, supporting confidence in sustained adoption and future upside.

Delcath Systems is facing a fundamental execution risk because accrual across both sponsored Phase 2 studies has fallen short of internal expectations, with the company losing some participating centers as interventional radiology groups and oncology teams struggled to coordinate around a liver-directed therapy they are new to. Although recruitment has improved through specialized training and streamlined onboarding, activated centers for mCRC remained flat QoQ at 13, signaling that operational progress is still fragile and not yet translating into broad trial momentum. The first patient was dosed in the Phase 2 DELUMA study in Milan and six sites are screening, but the interim mCRC readout is not expected until late 2027, extending uncertainty around clinical validation and commercialization.